Magnus Ingelman-Sundberg, PhD; BSc.Med is Professor of Molecular Toxicology since 1996 and research group leader in Pharmacogenetics at the Department of Physiology and Pharmacology , Karolinska Institutet since 2006. He has more than 420 original papers, 24 500 citations (32 000 in Google Scholar) and an h-factor of 85 (ISI) or 104 (Google Scholar). He is a member of The Nobel Assembly at Karolinska Institutet since 2008, a member of Academia Europaea and a member of Editorial Advisory Boards of e.g. Trends in Pharmacological Sciences (Edit Board), Pharmacogenetics and Genomics, Pharmacogenomics, Human Genomics, Drug Metabolism Reviews, Drug Metabolism and Disposition. His research focuses on genetics, epigenetics, polymorphism, regulation, function and toxicology of the hepatic ADME system with aims at understanding interindividual differences in drug response. Furthermore he develops novel hepatic in vitro systems for studying liver function and validation of drug targets. Further info from an Interview with Magnus Ingelman-Sundberg See: Trends Pharmacol Sci. 2015; 36:65-7.
